Mar 15, 2022 9:00am EDT Sigyn Therapeutics™ Appoints H. David Humes, MD to Its Scientific Advisory Board
Mar 09, 2022 9:00am EST Sigyn Therapeutics Appoints Alexander S. Yevzlin, MD, FASN to Its Scientific Advisory Board
Mar 02, 2022 8:00am EST Sigyn Therapeutics™ Appoints Accomplished Financial Executive, Jeremy Ferrell, as Chief Financial Officer
Jan 04, 2022 7:30am EST Sigyn Therapeutics CEO Note: 2021 Milestone Achievements / 2022 Clinical Progression / Images of Sigyn Therapy in Action
Dec 17, 2021 8:30am EST Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or Vaccines
Dec 01, 2021 7:30am EST Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis
Aug 30, 2021 7:30am EDT Sigyn Therapeutics Featured on National Public Radio: “Addressing the Cytokine Storm”
Aug 10, 2021 6:30am EDT Sigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory Disease Targets
